Beigene Ltd
NASDAQ:ONC

Watchlist Manager
Beigene Ltd Logo
Beigene Ltd
NASDAQ:ONC
Watchlist
Price: 350 USD Market Closed
Market Cap: $487.9B

Net Margin

-0.4%
Current
Improving
by 46.2%
vs 3-y average of -46.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-0.4%
=
Net Income
¥-153m
/
Revenue
¥35.7B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-0.4%
=
Net Income
$-153m
/
Revenue
¥35.7B

Peer Comparison

Country Company Market Cap Net
Margin
KY
Beigene Ltd
SSE:688235
255B CNY
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
395.2B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.2B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175.6B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.8B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.3B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

In line with most companies in Cayman Islands
Percentile
40th
Based on 101 companies
40th percentile
-0.4%
Low
-9 935.2% — -5.8%
Typical Range
-5.8% — 6.5%
High
6.5% — 36.5%
Distribution Statistics
Cayman Islands
Min -9 935.2%
30th Percentile -5.8%
Median -0.3%
70th Percentile 6.5%
Max 36.5%

Beigene Ltd
Glance View

Market Cap
487.9B USD
Industry
Biotechnology

BeiGene Ltd., a global powerhouse in biopharmaceutical innovation, traces its journey back to its roots in Beijing, having established itself with a clear vision—to address the vast unmet needs in cancer treatment. Co-founded by John V. Oyler in 2010, the company set out on a mission to develop effective and accessible therapies for cancer patients worldwide. Operating at the intersection of cutting-edge science and global entrepreneurship, BeiGene built its reputation by investing heavily in research and development. The crux of its model hinges on leveraging both in-house capabilities and strategic collaborations. This has allowed it to expedite the development of a rich pipeline of oncology therapies, with a focus on small molecule drugs and monoclonal antibodies, navigating the complex world of biotechnology to bring pioneering solutions to market. Central to BeiGene's financial engine is its adeptness at creating a portfolio of marketable cancer therapies, primarily through licensing agreements and strategic partnerships. The company's business model thrives on advancements like Brukinsa, a treatment for certain types of lymphoma, which has seen significant regulatory approvals worldwide. Partnerships with pharmaceutical giants, such as Amgen, have amplified its global reach, enabling it to widen its distribution network beyond China to North America and Europe. By embedding itself into various markets and healthcare systems, BeiGene captures revenue through product sales, milestone payments, royalties, and collaboration fees. This multifaceted approach not only spearheads its growth trajectory but also solidifies its reputation as a company committed to combating cancer on a global scale, driven by innovation and an unwavering dedication to its mission.

ONC Intrinsic Value
246.39 USD
Overvaluation 30%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-0.4%
=
Net Income
¥-153m
/
Revenue
¥35.7B
What is Beigene Ltd's current Net Margin?

The current Net Margin for Beigene Ltd is -0.4%, which is above its 3-year median of -46.7%.

How has Net Margin changed over time?

Over the last 3 years, Beigene Ltd’s Net Margin has increased from -178.4% to -0.4%. During this period, it reached a low of -178.4% on Sep 30, 2022 and a high of -0.4% on Sep 30, 2025.

Back to Top